H.C. Wainwright Reiterates Buy Rating on Cartesian Therapeutics (RNAC)

September 13, 2024 6:44 AM EDT Send to a Friend
H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $45.00 price target on Cartesian Therapeutics (NASDAQ: RNAC).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login